Nolasiban - ObsEva

Drug Profile

Nolasiban - ObsEva

Alternative Names: Erlosiban; OBE-001

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Developer ObsEva
  • Class Oximes; Pyrrolidinones; Small molecules; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Female infertility
  • Phase II Preterm labour

Most Recent Events

  • 01 Aug 2017 ObsEva completes enrolment in a phase III clinical trial in Female infertility in Belgium, Denmark, Estonia, Finland, Germany, Hungary, Poland, Spain and Ukraine (PO) (EudraCT2016-004266-25)
  • 29 Jun 2017 Efficacy data from the phase II IMPLANT trial for Female infertility released by ObsEva
  • 24 Apr 2017 Phase-III clinical trials in Female infertility in Estonia, Finland, Germany, Hungary, Ukraine (PO) (EudraCT2016-004266-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top